Management ChangeAug 3, 2026, 04:57 PM
Cue Biopharma Appoints James Ahlers as CFO
AI Summary
Cue Biopharma, Inc. announced the appointment of James Ahlers as its new Chief Financial Officer, effective July 30, 2026. Mr. Ahlers brings extensive experience as a CFO and strategic advisor to life sciences companies, including leadership in public and private financings, SEC reporting, and investor relations. His compensation package includes an annualized base salary of $450,000, a target annual bonus of up to 45% of his base salary, and initial grants of 51,000 stock options and 25,500 restricted stock units, vesting over four years.
Key Highlights
- James Ahlers appointed Chief Financial Officer, effective July 30, 2026.
- Mr. Ahlers will serve as the Company's principal financial officer.
- Annualized base salary set at $450,000.
- Eligible for discretionary annual incentive bonus with a target of up to 45% of base salary.
- Granted 51,000 nonstatutory stock options with an exercise price of $30.40.
- Granted 25,500 restricted stock units (RSUs).
- Initial grants vest in equal quarterly installments over four years.
- Severance includes 9 months base salary plus prorated target annual bonus for qualifying termination.
Price Impact
More from CUE